Non-Invasive Cervical-Cancer Test Studied
Posted on: Wednesday, 10 January 2007, 12:01 CST
U.S. firm SpectRx said Wednesday it is working on a non-invasive test for cervical cancer that could cut the rate of unnecessary biopsies in half.
The company said it is currently testing the new device at five clinical sites.
Recent advances in cervical cancer treatment and prevention are drawing more attention to the need for a more effective and humane method of detecting cervical disease that also helps to preserve the reproductive health of women, said Mark Faupel, SpectRx's chief technical officer. In addition to potentially reducing the pain and extra cost of following up on false-positive results, the study reported that our device was simple to use and was well accepted by test subjects.
One study involving 629 patients showed the device had a sensitivity as high as 95 percent, compared to the standard testing method called histopathology, the company said.
The new device tests for cervical cancer by analyzing light reflected from the cervix to distinguish between normal and diseased tissue.
Source: United Press International
Related Articles
- Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
- New Painless Test for Cervical Cancer Outperforms Tissue Sample Tests
- SpectRx Cervical-Cancer Test Advancing
- European Commission Approves GARDASIL(R), Merck's Cervical Cancer Vaccine
- National Cancer Institute Awards Fifth Grant to SpectRx, Inc. For Non-Invasive Cervical Cancer Detection Technology
- Diamics Inc.'s Proprietary Cervical Cancer Screening System to Be Presented at AACC Clinical Lab Expo
- Two Clinical Studies Indicate SpectRx Non-Invasive Cervical Cancer Detection Device Accurately Detects Disease While Reducing False Positive Results
- SpectRx, Inc. Granted Patent for Non-Invasive Cervical Cancer Detection Technology
- SpectRx, Inc. Granted Key Patent for Non-Invasive Cervical Cancer Detection Technology; Guided Therapeutics Device in FDA Pivotal Clinical Trial
 |
 |
User Comments (0)
RSS Feeds